DURABLE REMISSIONS WITH CONTROL OF CYTOKINE RELEASE SYNDROME (CRS) USING T CELLS EXPRESSING CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) CTL019 TO TREAT RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOID LEUKEMIA (ALL)

被引：1

作者：

Levine, B. L. ^{[1
,2
,3
]}

Maude, S. ^{[4
,5
,6
]}

Zheng, Z. ^{[1
,2
]}

Shaw, P. ^{[7
]}

Ambrose, D. ^{[1
]}

Aplenc, R. ^{[5
,6
]}

Barker, C. ^{[4
,5
,6
]}

Barrett, D. ^{[4
,5
,6
]}

Brogdon, J. ^{[8
]}

Callahan, C. ^{[5
,6
]}

Chen, F. ^{[1
]}

Chew, A. ^{[1
]}

Davis, M. M. Suhoski ^{[1
,2
]}

Fesnak, A. D. ^{[1
,2
]}

Finklestein, J. ^{[1
]}

Frey, N. ^{[8
]}

Lacey, S. ^{[1
]}

Lamontagne, A. ^{[1
,2
]}

Lewitt, L. ^{[1
,2
]}

Loew, A. ^{[8
]}

Marcucci, K. ^{[1
]}

Melenhorst, J. ^{[1
,2
]}

Motley, L. ^{[5
,6
]}

Mudambi, M. ^{[5
,6
]}

Nazimuddin, F. ^{[1
]}

O'Rourke, M. ^{[1
,2
]}

Porter, D. ^{[3
]}

Rheingold, S. R. ^{[5
,6
]}

Scholler, J. ^{[1
]}

Tayor, C. ^{[1
,2
]}

White, C. ^{[5
,6
]}

Wood, P. ^{[9
]}

Young, R. ^{[1
]}

Teachey, D. T. ^{[4
,5
,6
]}

June, C. ^{[1
,2
,3
]}

Grupp, S. ^{[3
,4
,5
,6
]}

机构：

[1] Univ Penn, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA

[2] Univ Penn, Pathol & Lab Med, Philadelphia, PA 19104 USA

[3] Abramson Canc Ctr, Philadelphia, PA USA

[4] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA

[5] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA

[6] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA

[7] Univ Penn, Biostat & Epidemiol, Philadelphia, PA 19104 USA

[8] Novartis Inst Biomed Res, Cambridge, MA USA

[9] Novartis Pharmaceut, Cell & Gene Therapies Unit, E Hanover, NJ USA

来源：

CYTOTHERAPY | 2016年 / 18卷 / 06期

关键词：

D O I：

10.1016/j.jcyt.2016.03.039

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

引用

页码：S14 / S15

页数：2

共 50 条

[21] Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/ refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression
Danylesko, Ivetta
Shem-Tov, Noga
Yerushalmi, Ronit
Jacoby, Elad
Toren, Amos
Shouval, Roni
Itzhaki, Orit
Avigdor, Abraham
Shimoni, Avichai
Nagler, Arnon
CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2024, 72 (04)
[22] Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Myers, Regina M.
Kadauke, Stephan
Li, Yimei
Callahan, Colleen A.
Gladney, Whitney
Fitzgerald, Julie C.
Wray, Lisa
Leahy, Allison Barz
Baniewicz, Diane
Motley, Laura S.
McGuire, Regina
Shenoy, Vikram
Barrett, David M.
Teachey, David T.
Maude, Shannon L.
DiNofia, Amanda
Grupp, Stephan A.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S39 - S39
[23] Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).
Schuster, Stephen J.
Svoboda, Jakub
Nasta, Sunita
Chong, Elise A.
Porter, David L.
Landsburg, Daniel Jeffrey
Mato, Anthony R.
Bhoj, Vijay G.
Milone, Michael
Lacey, Simon F.
Strelec, Lauren E.
Zhou, Alice Y.
Melenhorst, Jan J.
Chew, Anne
Hasskarl, Jens
Wasik, Mariusz A.
Marcucci, Katherine
Zheng, Zhaohui
Levine, Bruce
June, Carl H.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[24] Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Maude, Shannon L.
Hucks, George E.
Callahan, Colleen
Baniewicz, Diane
Fasano, Christina
Barker, Christine
Rheingold, Susan R.
Aplenc, Richard
Dinofia, Amanda M.
Li, Amanda
Teachey, David T.
Barrett, David M.
Brogdon, Jennifer
Young, Regina M.
Scholler, John
Marcucci, Katherine T.
Levine, Bruce L.
Frey, Noelle
Porter, David L.
Lacey, Simon F.
Melenhorst, J. Joseph
June, Carl H.
Grupp, Stephan A.
BLOOD, 2017, 130
[25] Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL
Maude, Shannon L.
Teachey, David T.
Rheingold, Susan R.
Shaw, Pamela A.
Aplenc, Richard
Barrett, David Maxwell
Barker, Christine S.
Callahan, Colleen
Frey, Noelle V.
Nazimuddin, Farzana
Lacey, Simon F.
Zheng, Zhaohui
Levine, Bruce
Melenhorst, Jan Joseph
Motley, Laura
Porter, David L.
June, Carl H.
Grupp, Stephan A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[26] T CELLS ENGINEERED WITH A CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING CD19 (CTL019 CELLS) PRODUCE SIGNIFICANT IN VIVO PROLIFERATION, COMPLETE RESPONSES AND LONG-TERM PERSISTENCE WITHOUT GVHD IN CHILDREN AND ADULTS WITH RELAPSED, REFRACTORY ALL
Grupp, S.
Frey, N.
Aplenc, R.
Levine, B.
Maude, S.
Rheingold, S.
Barker, C. Strait
Teachey, D.
Mahnke, Y.
Porter, D.
June, C.
BONE MARROW TRANSPLANTATION, 2014, 49 : S1 - S1
[27] T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL
Grupp, Stephan A.
Frey, Noelle V.
Aplenc, Richard
Barrett, David M.
Chew, Anne
Kalos, Michael
Levine, Bruce L.
Litchman, Manuel
Maude, Shannon L.
Rheingold, Susan R.
Shen, Angela
Strait, Christine
Teachey, David T.
Wood, Patricia A.
Porter, David
June, Carl H.
BLOOD, 2013, 122 (21)
[28] Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
Shi, Ming
Li, Li
Wang, Shiyuan
Cheng, Hai
Chen, Wei
Sang, Wei
Qi, Kunming
Li, Zhenyu
Wang, Gang
Li, Huizhong
Lan, Jianping
Huang, Jinqi
Fei, Xiaoming
Yu, Min
Li, Fei
Qiao, Jianlin
Wu, Qingyun
Zeng, Lingyu
Jing, Guangjun
Zheng, Junnian
Gale, Robert Peter
Xu, Kailin
Cao, Jiang
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : 711 - 718
[29] DURABLE REMISSIONS AFTER MONOTHERAPY WITH CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR)-MODIFIED T CELLS IN CHILDREN AND YOUNG ADULTS WITH RELAPSED/REFRACTORY ALL
Maude, S.
Teachey, D.
Rheingold, S.
Shaw, P.
Aplenc, R.
Barrett, D.
Barker, C.
Callahan, C.
Frey, N.
Nazimuddin, F.
Lacey, S.
Zheng, Z.
Levine, B.
Melenhorst, J.
Motley, L.
Porter, D.
June, C.
Grupp, S.
HAEMATOLOGICA, 2016, 101 : 183 - 184
[30] Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).
Frey, Noelle V.
Shaw, Pamela A.
Hexner, Elizabeth O.
Gill, Saar
Marcucci, Katherine
Luger, Selina M.
Mangan, James K.
Grupp, Stephan A.
Maude, Shannon L.
Ericson, Solveig
Levine, Bruce
Lacey, Simon F.
Melenhorst, Jan J.
June, Carl H.
Porter, David L.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →